FDA halts the use of GSK's Covid-19 drug com­plete­ly as BA.2 sub­vari­ant blan­kets the coun­try

It on­ly took the Omi­cron BA.2 sub­vari­ant three busi­ness days to go from shut­ting down Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s Covid-19 treat­ment sotro­vimab in 22 states, as of last Fri­day, to the FDA com­plete­ly shut­ting off use of the mon­o­clon­al an­ti­body na­tion­wide on Tues­day af­ter­noon.

The de­ci­sion was made as the CDC now es­ti­mates that the pro­por­tion of Covid-19 cas­es caused by BA.2 is above 50% na­tion­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER